FDA Clears Philips' AlluraClarity Interventional X-Ray System

Low X-ray dose settings help clinicians to manage radiation exposure

 

July 8, 2013

Philips Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AlluraClarity live image guidance system in the United States.

Philips’ AlluraClarity system with its powerful ClarityIQ technology provides high-quality imaging for a comprehensive range of clinical procedures, achieving excellent visibility at low X-ray dose levels for patients of all sizes. ClarityIQ technology will also be available as an upgrade for the majority of Philips’ installed base of monoplane and biplane interventional X-ray systems.

Philips’ AlluraClarity was commercially introduced outside the United States in mid-2012, and since then more than 200 systems have been ordered.

It received FDA clearance in July 2013.

For more information: philips.us/AlluraClarity.